| abstract |
Compounds that form covalent bonds with Bruton tyrosine kinase (BTK) are described herein. The methods for preparing the compounds are described. Pharmaceutical compositions that include the compounds are also described. The methods of use of BTK inhibitors, alone or in combination with other therapeutic agents, are described for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma and inflammatory diseases or conditions. |